Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease

Endocrinol Metab Clin North Am. 2023 Sep;52(3):459-468. doi: 10.1016/j.ecl.2023.01.002. Epub 2023 Mar 8.


Both nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) have been associated with incident cardiovascular disease (CVD), independent of confounders. Causality has recently been inferred by Mendelian randomization studies. Although these findings have contributed to current guidelines that recommend screening for and treatment of cardiovascular risk factors, it not yet clear how to position NAFLD/MAFLD in cardiovascular risk estimation scores and, consequently, which treatment targets should be used. This review aims to provide practical tools as well as suggestions for further research in order to effectively prevent CVD events in patients with NAFLD/MAFLD.

Keywords: Cardiovascular disease; Metabolic dysfunction-associated fatty liver disease; Nonalcoholic fatty liver disease; Preventive measures; Treatment.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases*
  • Cardiovascular System
  • Metabolic Diseases*
  • Non-alcoholic Fatty Liver Disease*